A 48-year-old man with bipolar I disorder has been stable on lithium carbonate 1000 mg daily (serum level 0.9 mEq/L) for 18 months. He is started on a thiazide diuretic (hydrochlorothiazide 25 mg daily) for newly diagnosed hypertension. Two weeks later, he develops polyuria, polydipsia, and tremor. Repeat serum lithium level is 1.8 mEq/L. Serum sodium 136 mEq/L (normal 135–145), serum creatinine 1.0 mg/dL. Urine osmolality is 250 mOsm/kg (normal >600). What is the most appropriate next step in management?

Explanation

## Drug–Drug Interaction: Lithium and Thiazide Diuretics **Key Point:** Thiazide diuretics reduce renal lithium clearance by 20–40%, leading to elevated serum lithium levels and toxicity risk. This patient's lithium level doubled (0.9 → 1.8 mEq/L) after thiazide initiation, despite unchanged lithium dosing. ## Mechanism of Lithium–Thiazide Interaction 1. Thiazides cause mild volume depletion and hyponatremia 2. The kidneys increase proximal tubular reabsorption of sodium (and lithium, which competes with sodium) 3. Distal tubular secretion of lithium is also reduced 4. Net result: ↓ renal lithium clearance → ↑ serum lithium level **High-Yield:** The combination of thiazide diuretics + lithium is a classic high-risk drug interaction tested frequently in NEET PG. The serum sodium is already at the lower end of normal (136 mEq/L), indicating mild hyponatremia from the thiazide. ## Antihypertensive Agents and Lithium: Comparative Safety | Antihypertensive Class | Effect on Lithium Clearance | Recommendation | |------------------------|------------------------------|----------------| | **Thiazide diuretics** | ↓↓ (reduce clearance 20–40%) | **AVOID** | | **Loop diuretics** | ↓ (reduce clearance 10–20%) | Use with caution, monitor closely | | **ACE inhibitors** | ↓ (modest reduction) | Monitor lithium levels | | **Calcium channel blockers** | ↔ (no significant effect) | **SAFE alternative** | | **Beta-blockers** | ↔ (no significant effect) | Safe | | **Potassium-sparing diuretics** | ↔ (no effect on clearance) | Safe for HTN + lithium | **Clinical Pearl:** When a patient on lithium requires antihypertensive therapy, calcium channel blockers (nifedipine, diltiazem) or beta-blockers are preferred first-line agents because they do not affect lithium clearance. If a diuretic is necessary, loop diuretics or potassium-sparing agents (spironolactone, amiloride) are safer than thiazides. ## Management Strategy ```mermaid flowchart TD A[Patient on lithium + thiazide with ↑ Li+ level]:::outcome --> B{What is the cause?}:::decision B -->|Thiazide-induced reduction in clearance| C[Discontinue thiazide]:::action C --> D[Switch to safer antihypertensive]:::action D --> E{Which agent?}:::decision E -->|Preferred: CCB or beta-blocker| F[Nifedipine or amlodipine]:::action E -->|Alternative: K-sparing diuretic| G[Amiloride or spironolactone]:::action F --> H[Reduce lithium dose by 25-50%]:::action G --> H H --> I[Recheck Li+ level in 5-7 days]:::action I --> J{Li+ 0.6-1.0 mEq/L?}:::decision J -->|Yes| K[Stable; continue monitoring]:::outcome J -->|No| L[Further adjust lithium dose]:::action ``` **Warning:** Option A (continue thiazide, increase lithium) is dangerous—it perpetuates the drug interaction and risks further lithium accumulation. Option C (reduce lithium 50% while keeping thiazide) is a compromise but suboptimal because the thiazide interaction persists. Option D (amiloride as add-on) is a valid strategy in some guidelines but is secondary to switching the antihypertensive agent.